Skip to Content

Media Releases

 


Corporate News

May 16, 2012
Roche will report new data on important progress for people with advanced cancers at ASCO 2012
Roche today announced that the company will present important new data from studies of several of its cancer medicines at ... more

May 07, 2012
Roche provides update on Phase III study of dalcetrapib
Roche today announced that following the results of the second interim analysis of the dalcetrapib dal-OUTCOMES Phase III ... more

May 03, 2012
Roche reports positive study of RoACTEMRA given by subcutaneous injection
Roche today announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy of the subcutaneous (SC) ... more

April 18, 2012
Roche decides not to extend its tender offer for Illumina, Inc.
Roche released the following statement based on preliminary estimates indicating the re-election of the incumbent directors ... more

April 12, 2012
Roche on track for full-year targets - good sales growth in first quarter
Group sales rise 2% at CER (-1% in Swiss francs; +1% in US dollars) to 11.0 billion Swiss francs. Excluding Tamiflu, sales ... more

April 12, 2012
Roche issues statement regarding Illumina offer
Roche released the following statement regarding its pending offer for Illumina, Inc. (NASDAQ: ILMN) more

April 11, 2012
Roche sends open letter to Illumina shareholders
Roche today sent an open letter to shareholders of Illumina, Inc. (NASDAQ: ILMN) urging them to vote the GOLD proxy card for ... more

April 06, 2012
Roche disappointed with ISS recommendation
Roche released the following statement in response to a report issued by Institutional Shareholder Services (“ISS”) ... more

April 04, 2012
Roche sends second letter to Illumina shareholders
Roche (SIX: RO, ROG; OTCQX: RHHBY) today sent a second letter to shareholders of Illumina, Inc. (NASDAQ: ILMN) urging them ... more

April 03, 2012
Roche disappointed by Illumina, Inc.'s Board of Directors' rejection
By not engaging with Roche, Illumina reinforces notion of an entrenched Board. Roche released the following statement in response ... more

March 30, 2012
Roche's trastuzumab emtansine (T-DM1) showed positive Phase III results in HER2-positive metastatic breast cancer
Roche today announced topline results of EMILIA, the first randomised Phase III study of trastuzumab emtansine (T-DM1). more

March 29, 2012
Roche increases offer price for Illumina shares to US$ 51.00 per share
Roche announced today that it has increased its offer price for all outstanding publicly-held shares of Illumina, Inc. (NASDAQ: ... more

March 26, 2012
Roche extends tender offer for Illumina
Roche announced today that it has extended its cash tender offer to acquire all outstanding shares of Illumina, Inc. (NASDAQ: ... more

March 23, 2012
Roche's Herceptin given by subcutaneous injection offers greater convenience to patients and reduces overall healthcare costs compared to standard IV infusion
Subcutaneous administration of Herceptin is less invasive and takes approximately 5 minutes instead of 30-90 minutes with ... more

March 20, 2012
Roche files definitive proxy statement
Roche today announced that it filed its definitive proxy statement and sent a letter to shareholders of Illumina, Inc. (NASDAQ: ... more

March 13, 2012
Roche receives request for additional information from the Federal Trade Commission
Roche announced today that it has received a request for additional information, often referred to as a “second request,” ... more

March 12, 2012
Second Transnet-Phelophepa Healthcare Train inaugurated in South Africa
Roche doubles its support for unique project providing healthcare to reach 90,000 patients a year in rural South Africa. Today, ... more

March 06, 2012
Roche Annual General Meeting 2012
Roche's Annual General Meeting, held today in Basel, approved all of the Board of Directors' proposals. The 755 ... more

March 02, 2012
Roche's RoACTEMRA monotherapy showed superior improvement in rheumatoid arthritis signs and symptoms versus adalimumab monotherapy
Roche today announced that preliminary results from the ADACTA study (ADalimumab ACTemrA) showed that patients who received ... more

February 27, 2012
Roche extends tender offer for Illumina
Roche announced today that it has extended its cash tender offer to acquire all outstanding shares of Illumina, Inc. (NASDAQ: ... more

February 20, 2012
Roche's Zelboraf receives EU approval for the treatment of people with deadly form of skin cancer
First and only personalized skin cancer medicine allows people with BRAF V600 mutation-positive metastatic melanoma to live ... more

February 08, 2012
FDA grants Roche's pertuzumab Priority Review for previously untreated HER2-positive metastatic breast cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License ... more

February 08, 2012
Roche disappointed by the actions of Illumina, Inc.'s Board of Directors
Roche released the following statement in response to the announcement by Illumina, Inc. that its Board of Directors has recommended ... more

February 01, 2012
Roche in 2011: Strong results and positive outlook
Group sales rise 2% 1 (-10% in Swiss francs; +6% in US dollars), excluding Tamiflu; Significant foreign exchange impact of ... more

January 31, 2012
Roche to nominate slate of independent directors for election at Illumina, Inc.'s 2012 annual meeting
Roche announced today that it has provided notice to Illumina, Inc. (NASDAQ: ILMN) that it will nominate a slate of highly ... more

January 30, 2012
FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma
Roche today announced that Erivedge (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for adults ... more

January 27, 2012
Roche commences tender offer for Illumina, Inc. for $44.50 per share in cash
Roche, a leader in research-focused healthcare with combined strengths in pharmaceuticals, life science tools and diagnostics, ... more

January 27, 2012
Roche responds to adoption of shareholder rights plan by Illumina Board of Directors
Roche today responded to an announcement from Illumina, Inc. (NASDAQ: ILMN) that its Board of Directors has adopted a shareholder ... more

January 25, 2012
Roche offers to acquire all outstanding shares of Illumina, Inc. to further strengthen its leading role in diagnostics
Roche announced today that it is proposing to acquire all outstanding shares of Illumina, Inc. (NASDAQ:ILMN) for $44.50 per ... more

January 23, 2012
Roche supports cancer care development program in Ethiopia
Roche today announced a grant to the Albert Einstein College of Medicine of Yeshiva University in New York City, which will ... more

Trade News